Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight

Morgan Stanley analyst Michael Ulz downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Equal-Weight to Underweight.
byBenzinga Newsdesk
January 27, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Michael Ulz downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Equal-Weight to Underweight.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts